Cancer News and Research

Latest Cancer News and Research

Patients switching to Victoza experience further reductions in A1c and weight loss

Diabetes Care published online the results of the Novo Nordisk LEAD™ 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily Victoza®. Results show that when added to oral antidiabetes drugs, patients who switched from exenatide to Victoza experienced further reductions in A1c and weight loss.

31 Mar 2010

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

QRxPharma announced today initiation of the Company's first Phase 1 trial to evaluate the pharmacokinetic (PK) profiles of experimental controlled-release (CR) morphine and oxycodone formulations that will be incorporated into MoxDuo®CR. MoxDuo®CR contains a fixed 3:2 morphine:oxycodone combination and is intended to be dosed twice daily in patients experiencing chronic pain, an approximately US$7 billion dollar market worldwide.

31 Mar 2010

Close-ups on how the health overhaul gives and takes away

"An association representing 300 large corporations urged President Obama and Congress on Monday to repeal a provision of the health care overhaul that prompted AT&T, Caterpillar and other companies to announce substantial charges for the current quarter."

31 Mar 2010

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

YM BioSciences Inc., announced that it has received ethics board approval to expand enrolment in its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis, a chronic debilitating condition, where patient's bone marrow is replaced by scar tissue.

31 Mar 2010

Facts and treatment options for endometriosis

One out of every two women struggling to conceive may suffer from endometriosis - the leading cause of infertility - according to research from Camran Nezhat, M.D., gynecologist at El Camino Hospital, the hospital of the Silicon Valley.

31 Mar 2010

Access Pharmaceuticals, bioRASI sign collaborative agreement to develop Cobalamin oral insulin product

ACCESS PHARMACEUTICALS, INC. signed a collaborative development agreement with bioRASI, LLC, a full-service global CRO specializing in the accelerated development of novel therapeutics, to facilitate clinical development for its Cobalamin™-based oral insulin and other Cobalamin-based products.

31 Mar 2010

FDA allows GeoVax Labs to commence phase 1 clinical trial for HIV/AIDS therapeutic vaccine

GeoVax Labs, Inc., a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, is now allowed by the FDA to begin a phase 1 clinical trial for GeoVax's therapeutic vaccine, which is intended as a treatment for individuals infected with HIV. The company will begin a non-blinded study in HIV infected individuals who started drug treatment during their first year of infection.

30 Mar 2010

Ascent Therapeutics is now Anchor Therapeutics

Ascent Therapeutics announced today that it has adopted a new name — Anchor Therapeutics. Anchor Therapeutics reflects the Company's core technology and its commitment to building solid, dependable value for patients, partners and investors via its proprietary platform technology.

30 Mar 2010

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs.

30 Mar 2010

Savient Pharmaceuticals' resubmission of BLA for KRYSTEXXA accepted for FDA review

Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has acknowledged receipt of and accepted for review the March 15, 2010 resubmission of the Biologics License Application for KRYSTEXXA™ (pegloticase), a treatment for chronic gout in patients refractory to conventional therapy.

30 Mar 2010

Neuroscientists prevent memory loss in fruit flies by blocking activity of PI3 kinase signaling protein

By blocking the cellular signaling activity of a protein, a team of neuroscientists at Cold Spring Harbor Laboratory (CSHL) has prevented memory loss in fruit flies caused by brain plaques similar to those thought to cause Alzheimer's disease in humans. The study also resolves a long-standing controversy about the role of this protein, PI3 kinase, which was previously thought to have a protective function against the disease.

30 Mar 2010

Euthanasia: Defining actions and terms, and promoting honest debate needed

It is time to discard the word euthanasia because it mixes ideas and values that confuses the debate about dying, states an editorial in CMAJ (Canadian Medical Association Journal)

30 Mar 2010

Court rules certain claims covering isolated DNA sequences in patents covering BRACAnalysis as invalid

Myriad Genetics, Inc. today announced that Judge Robert W. Sweet of the Federal District Court for the Southern District of New York ruled that certain claims covering isolated DNA sequences in seven of the 23 patents covering BRACAnalysis® are invalid. Myriad will appeal the decision to the Court of Appeals for the Federal Circuit and will continue to vigorously defend this litigation.

30 Mar 2010

Virginia Tech professor receives NSF CAREER award for research on cancer therapies using nanotechnology

Preliminary research on cancer treatments using nanotechnology and laser therapy has led to a National Science Foundation (NSF) Faculty Early Career Development (CAREER) award for Marissa Nichole Rylander, Virginia Tech assistant professor jointly appointed in the Department of Mechanical Engineering and Virginia Tech - Wake Forest University School of Biomedical Engineering and Sciences (SBES).

30 Mar 2010

Insight into scorpion venom may help understand diseases like pancreatitis

A Brazilian scorpion has provided researchers at North Carolina State University and East Carolina University insight into venom's effects on the ability of certain cells to release critical components. The findings may prove useful in understanding diseases like pancreatitis or in targeted drug delivery.

30 Mar 2010

Chocolate can lower blood pressure and reduce risk of heart disease: Study

Easter eggs and other chocolate may be good for you - at least in small quantities and preferably if it's dark chocolate - according to research that shows just one small square of chocolate a day can lower your blood pressure and reduce your risk of heart disease. The study is published online today (Wednesday 31 March) in the European Heart Journal.

30 Mar 2010

Researchers find Dpp protein causes metastatic tumour migration

One of the most intriguing questions in cancer research is what causes metastatic tumour migration, why some tumour cells manage to migrate to other parts of the body but others cells don't. International investigation conducted by Enrique Mart-n Blanco, CSIC researcher at the Institute of Biology of Barcelona, located in the Barcelona Science Park, reveals that cells make use of a natural mechanism for this.

30 Mar 2010

Development and validation process of Rosetta Genomics' miRview mets published

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announces publication of an article describing the development and validation process of miRview™ mets, the company's microRNA-based test for identification of primary origin of metastases.

30 Mar 2010

Preventive health care researchers meet to outline vision for evidence-based prevention in health care

Leading preventive health care researchers, physicians and executives assembled at U.S. Preventive Medicine® Friday to outline their vision for advancing evidence-based prevention in health care.

30 Mar 2010

Analysis indicates substantial underdiagnosis of obesity when BMI used compared to DEXA scan

A retrospective analysis of 1,234 Americans indicated a substantial underdiagnosis of obesity when Body Mass Index was used compared to the Dual Energy X-ray Absorptiometry scan. This analysis will be released on Friday, April 23, 2010 at the American Association of Clinical Endocrinologists 19th Annual Meeting & Clinical Congress in Boston.

30 Mar 2010

Cancer News and Research

Latest Cancer News and Research

Patients switching to Victoza experience further reductions in A1c and weight loss

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

Close-ups on how the health overhaul gives and takes away

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

Facts and treatment options for endometriosis

Access Pharmaceuticals, bioRASI sign collaborative agreement to develop Cobalamin oral insulin product

FDA allows GeoVax Labs to commence phase 1 clinical trial for HIV/AIDS therapeutic vaccine

Ascent Therapeutics is now Anchor Therapeutics

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Savient Pharmaceuticals' resubmission of BLA for KRYSTEXXA accepted for FDA review

Neuroscientists prevent memory loss in fruit flies by blocking activity of PI3 kinase signaling protein

Euthanasia: Defining actions and terms, and promoting honest debate needed

Court rules certain claims covering isolated DNA sequences in patents covering BRACAnalysis as invalid

Virginia Tech professor receives NSF CAREER award for research on cancer therapies using nanotechnology

Insight into scorpion venom may help understand diseases like pancreatitis

Chocolate can lower blood pressure and reduce risk of heart disease: Study

Researchers find Dpp protein causes metastatic tumour migration

Development and validation process of Rosetta Genomics' miRview mets published

Preventive health care researchers meet to outline vision for evidence-based prevention in health care

Analysis indicates substantial underdiagnosis of obesity when BMI used compared to DEXA scan

Industry Focus eBook: Oncology eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook: Oncology eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in